IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset

Journal of Clinical Investigation

Volumn 124, Issue 9, 2014, Pages 3725-3740

  Sag, Duygu ^a   Krause, Petra ^a   Hedrick, Catherine C ^a   Kronenberg, Mitchell ^a   Wingender, Gerhard ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CYTOKINE; INTERLEUKIN 10; T LYMPHOCYTE RECEPTOR; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; GAMMA INTERFERON;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER T CELL; NKT10 CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GALACTOSYLCERAMIDES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NATURAL KILLER T-CELLS;

EID: 84907008497     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72308     Document Type: Article

References (72)

1. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336.
2. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol. 2002;2(8):557-568.
3. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol. 2005;23(1):877-900.
4. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest. 2004;114(10):1379-1388.
5. Wingender G, Kronenberg M. Role of NKT cells in the digestive system. IV. The role of canonical natural killer T cells in mucosal immunity and inflammation. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G1-G8.
6. Fujii S, et al. Adjuvant activity mediated by iNKT cells. Semin Immunol. 2010;22(2):97-102.
7. Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev. 2009;9(1):28-38.
8. Burdin N, Brossay L, Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol. 1999;29(6):2014-2025.
9. Parekh VV, et al. Glycolipid antigen induces longterm natural killer T cell anergy in mice. J Clin Invest. 2005;115(9):2572-2583.
10. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nat Immunol. 2002;3(9):867-874.
11. Sullivan BA, Kronenberg M. Activation or anergy: NKT cells are stunned by alpha-galactosylceramide. J Clin Invest. 2005;115(9):2328-2329.
12. Uldrich AP, et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol. 2005;175(5):3092-3101.
13. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-322.
14. Boussiotis VA, et al. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med. 2000;6(3):290-297.
15. Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21(1):305-334.
16. Wingender G, Krebs P, Beutler B, Kronenberg M. Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency. J Immunol. 2010;185(5):2721-2729.
17. Betts M. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281(1-2):65-78.
18. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001;13(4):459-463.
19. Smyth MJ, et al. Sequential production of interferon- γ by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood. 2002;99(4):1259-1266.
20. Moran AE, et al. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med. 2011;208(6):1279-1289.
21. Sullivan BA, et al. Mechanisms for glycolipid antigen-driven cytokine polarization by Vα14i NKT cells. J Immunol. 2010;184(1):141-153.
22. Nagarajan NA, Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. J Immunol. 2007;178(5):2706-2713.
23. Tyznik AJ, et al. Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals. J Immunol. 2008;181(7):4452-4456.
24. Iyoda T, et al. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus costimulation. Int Immunol. 2010;22(11):905-913.
25. Tonti E, et al. Follicular helper NKT cells induce limited B cell responses and germinal center formation in the absence of CD4(+) T cell help. J Immunol. 2012;188(7):3217-3222.
26. Chang P-P, et al. Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nat Immunol. 2011;13(1):35-43.
27. Baine I, Abe BT, Macián F. Regulation of T-cell tolerance by calcium/NFAT signaling. Immunol Rev. 2009;231(1):225-240.
28. Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO Rep. 2008;9(1):50-55.
29. Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol. 2011;707:3-17.
30. Madan R, et al. Nonredundant roles for B cellderived IL-10 in immune counter-regulation. J Immunol. 2009;183(4):2312-2320.
31. Corish P, Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng. 1999;12(12):1035-1040.
32. Biburger M, Tiegs G. Activation-induced NKT cell hyporesponsiveness protects from α-galactosylceramide hepatitis and is independent of active transregulatory factors. J Leukoc Biol. 2008;84(1):264-279.
33. Constantinides MG, Bendelac A. Transcriptional regulation of the NKT cell lineage. Curr Opin Immunol. 2013;25(2):161-167.
34. Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol. 2013;14(11):1146-1154.
35. Watarai H, et al. Development and function of invariant natural killer T cells producing T(h)2- and T(h)17-cytokines. PLoS Biol. 2012;10(2):e1001255.
36. Moreira-Teixeira L, et al. Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive Foxp3+ regulatory cells. J Immunol. 2012;188(2):624-631.
37. Monteiro M, et al. Identification of regulatory Foxp3+ invariant NKT cells induced by TGF-β. J Immunol. 2010;185(4):2157-2163.
38. King IL, et al. Invariant natural killer T cells direct B cell responses to cognate lipid antigen in an IL-21-dependent manner. Nat Immunol. 2011;13(1):44-50.
39. Milpied P, et al. IL-17-producing invariant NKT cells in lymphoid organs are recent thymic emigrants identified by neuropilin-1 expression. Blood. 2011;118(11):2993-3002.
40. Coquet JM, et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A. 2008;105(32):11287-11292.
41. Michel ML, et al. Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia. J Exp Med. 2007;204(5):995-1001.
42. Doisne JM, et al. Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor (gamma)t+ and respond preferentially under inflammatory conditions. J Immunol. 2009;183(3):2142-2149.
43. Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol. 2007;7(11):904-912.
44. Singh AK, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med. 2001;194(12):1801-1811.
45. Jahng AW, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med. 2001;194(12):1789-1799.
46. Furlan R, et al. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55-induced EAE: critical roles for administration route and IFN-γ. Eur J Immunol. 2003;33(7):1830-1838.
47. Parekh VV, et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J Immunol. 2004;173(6):3693-3706.
48. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 2001;413(6855):531-534.
49. Pal E, et al. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells. J Immunol. 2001;166(1):662-668.
50. Qian G, et al. High doses of α-galactosylceramide potentiate experimental autoimmune encephalomyelitis by directly enhancing Th17 response. Cell Res. 2010;20(4):480-491.
51. Wilson MT, et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci U S A. 2003;100(19):10913-10918.
52. Crowe NY, et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol. 2003;171(8):4020-4027.
53. Huh JY, et al. A novel function of adipocytes in lipid antigen presentation to iNKT cells. Mol Cell Biol. 2013;33(2):328-339.
54. Ji Y, et al. Activation of natural killer T cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity. J Biol Chem. 2012;287(17):13561-13571.
55. Lynch L, et al. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity. 2012;37(3):574-587.
56. Parekh VV, et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol. 2009;182(5):2816-2826.
57. Terashima A, et al. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J Exp Med. 2008;205(12):2727-2733.
58. Sonoda KH, et al. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol. 2001;166(1):42-50.
59. Lynch L, et al. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol. 2009;39(7):1893-1901.
60. Schipper HS, et al. Natural killer T cells in adipose tissue prevent insulin resistance. J Clin Invest. 2012;122(9):3343-3354.
61. Mars LT, et al. Cutting edge: Vα14-Jα281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J Immunol. 2002;168(12):6007-6011.
62. Singh N, et al. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol. 1999;163(5):2373-2377.
63. Matsuda JL, et al. Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci U S A. 2003;100(14):8395-8400.
64. Oh SJ, Chung DH. Invariant NKT cells producing IL-4 or IL-10, but not IFN-γ, inhibit the Th1 response in experimental autoimmune encephalomyelitis, whereas none of these cells inhibits the Th17 response. J Immunol. 2011;186(12):6815-6821.
65. Denney L, et al. Activation of invariant NKT cells in early phase of experimental autoimmune encephalomyelitis results in differentiation of Ly6Chi inflammatory monocyte to M2 macrophages and improved outcome. J Immunol. 2012;189(2):551-557.
66. Parekh VV, Wu L, Olivares-Villagómez D, Wilson KT, Van Kaer L. Activated invariant NKT cells control central nervous system autoimmunity in a mechanism that involves myeloid-derived suppressor cells. J Immunol. 2013;190(5):1948-1960.
67. Mars LT, et al. Invariant NKT cells inhibit development of the Th17 lineage. Proc Natl Acad Sci U S A. 2009;106(15):6238-6243.
68. Kojo S, et al. Induction of regulatory properties in dendritic cells by Vα14 NKT cells. J Immunol. 2005;175(6):3648-3655.
69. Sharif S, et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med. 2001;7(9):1057-1062.
70. Hong S, et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med. 2001;7(9):1052-1056.
71. Wingender G, et al. Invariant NKT cells are required for airway inflammation induced by environmental antigens. J Exp Med. 2011;208(6):1151-1162.
72. Barrett T, et al. NCBI GEO: archive for functional genomics data sets - 10 years on. Nucleic Acids Res. 2010;39(Database issue):D1005-D1010.